IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Fundamental Analysis & Valuation

NASDAQ:IMCR • US45258D1054

Current stock price

29.44 USD
-1.07 (-3.51%)
At close:
29.44 USD
0 (0%)
After Hours:

This IMCR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. IMCR Profitability Analysis

1.1 Basic Checks

  • IMCR had negative earnings in the past year.
  • In the past year IMCR has reported a negative cash flow from operations.
  • In the past 5 years IMCR always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: IMCR reported negative operating cash flow in multiple years.
IMCR Yearly Net Income VS EBIT VS OCF VS FCFIMCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • IMCR has a better Return On Assets (-3.33%) than 86.32% of its industry peers.
  • IMCR's Return On Equity of -9.32% is amongst the best of the industry. IMCR outperforms 87.09% of its industry peers.
Industry RankSector Rank
ROA -3.33%
ROE -9.32%
ROIC N/A
ROA(3y)-5.88%
ROA(5y)-14.14%
ROE(3y)-12.82%
ROE(5y)-25.99%
ROIC(3y)N/A
ROIC(5y)N/A
IMCR Yearly ROA, ROE, ROICIMCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • IMCR has a better Gross Margin (98.73%) than 97.69% of its industry peers.
  • IMCR's Gross Margin has been stable in the last couple of years.
  • IMCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5YN/A
IMCR Yearly Profit, Operating, Gross MarginsIMCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IMCR Health Analysis

2.1 Basic Checks

  • IMCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMCR has been increased compared to 1 year ago.
  • Compared to 5 years ago, IMCR has more shares outstanding
  • The debt/assets ratio for IMCR has been reduced compared to a year ago.
IMCR Yearly Shares OutstandingIMCR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
IMCR Yearly Total Debt VS Total AssetsIMCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.29, we must say that IMCR is in the distress zone and has some risk of bankruptcy.
  • IMCR has a Altman-Z score of 1.29. This is in the better half of the industry: IMCR outperforms 63.78% of its industry peers.
  • A Debt/Equity ratio of 1.03 is on the high side and indicates that IMCR has dependencies on debt financing.
  • IMCR has a Debt to Equity ratio of 1.03. This is in the lower half of the industry: IMCR underperforms 75.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z 1.29
ROIC/WACCN/A
WACC7.81%
IMCR Yearly LT Debt VS Equity VS FCFIMCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 4.04 indicates that IMCR has no problem at all paying its short term obligations.
  • The Current ratio of IMCR (4.04) is comparable to the rest of the industry.
  • A Quick Ratio of 4.01 indicates that IMCR has no problem at all paying its short term obligations.
  • The Quick ratio of IMCR (4.01) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 4.01
IMCR Yearly Current Assets VS Current LiabilitesIMCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IMCR Growth Analysis

3.1 Past

  • IMCR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.37%, which is quite impressive.
  • IMCR shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.95%.
  • Measured over the past years, IMCR shows a very strong growth in Revenue. The Revenue has been growing by 67.77% on average per year.
EPS 1Y (TTM)31.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.66%
Revenue 1Y (TTM)28.95%
Revenue growth 3Y40.67%
Revenue growth 5Y67.77%
Sales Q2Q%24.3%

3.2 Future

  • Based on estimates for the next years, IMCR will show a very strong growth in Earnings Per Share. The EPS will grow by 61.56% on average per year.
  • Based on estimates for the next years, IMCR will show a very strong growth in Revenue. The Revenue will grow by 20.80% on average per year.
EPS Next Y-53.8%
EPS Next 2Y-34.14%
EPS Next 3Y43.1%
EPS Next 5Y61.56%
Revenue Next Year11.62%
Revenue Next 2Y9.9%
Revenue Next 3Y12.72%
Revenue Next 5Y20.8%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IMCR Yearly Revenue VS EstimatesIMCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
IMCR Yearly EPS VS EstimatesIMCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. IMCR Valuation Analysis

4.1 Price/Earnings Ratio

  • IMCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCR Price Earnings VS Forward Price EarningsIMCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMCR Per share dataIMCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • IMCR's earnings are expected to grow with 43.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.14%
EPS Next 3Y43.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMCR Dividend Analysis

5.1 Amount

  • No dividends for IMCR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMCR Fundamentals: All Metrics, Ratios and Statistics

IMMUNOCORE HOLDINGS PLC-ADR

NASDAQ:IMCR (3/27/2026, 8:25:59 PM)

After market: 29.44 0 (0%)

29.44

-1.07 (-3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners104.27%
Inst Owner Change-6.34%
Ins Owners0.05%
Ins Owner Change37.69%
Market Cap1.49B
Revenue(TTM)400.02M
Net Income(TTM)-35.51M
Analysts83.48
Price Target68.07 (131.22%)
Short Float %24.27%
Short Ratio27.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.93%
Min EPS beat(2)-141.86%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-141.86%
Max EPS beat(4)125.17%
EPS beat(8)5
Avg EPS beat(8)21.43%
EPS beat(12)7
Avg EPS beat(12)20.91%
EPS beat(16)10
Avg EPS beat(16)-129381%
Revenue beat(2)1
Avg Revenue beat(2)-1.54%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)1.47%
Revenue beat(4)3
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.98%
Revenue beat(12)5
Avg Revenue beat(12)-1.69%
Revenue beat(16)8
Avg Revenue beat(16)13.87%
PT rev (1m)-1.77%
PT rev (3m)-2.44%
EPS NQ rev (1m)-63.08%
EPS NQ rev (3m)-39.47%
EPS NY rev (1m)-2.21%
EPS NY rev (3m)8.32%
Revenue NQ rev (1m)-2.37%
Revenue NQ rev (3m)-2.37%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.73
P/FCF N/A
P/OCF N/A
P/B 3.92
P/tB 3.92
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS7.89
BVpS7.52
TBVpS7.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.33%
ROE -9.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.73%
FCFM N/A
ROA(3y)-5.88%
ROA(5y)-14.14%
ROE(3y)-12.82%
ROE(5y)-25.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 132.88%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 4.01
Altman-Z 1.29
F-Score4
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)129.53%
Cap/Depr(5y)87.77%
Cap/Sales(3y)1.64%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.66%
EPS Next Y-53.8%
EPS Next 2Y-34.14%
EPS Next 3Y43.1%
EPS Next 5Y61.56%
Revenue 1Y (TTM)28.95%
Revenue growth 3Y40.67%
Revenue growth 5Y67.77%
Sales Q2Q%24.3%
Revenue Next Year11.62%
Revenue Next 2Y9.9%
Revenue Next 3Y12.72%
Revenue Next 5Y20.8%
EBIT growth 1Y35.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.26%
EBIT Next 3Y29.62%
EBIT Next 5Y58.86%
FCF growth 1Y-172.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.1%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOCORE HOLDINGS PLC-ADR / IMCR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMCR.


What is the valuation status for IMCR stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUNOCORE HOLDINGS PLC-ADR (IMCR). This can be considered as Overvalued.


How profitable is IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?

IMMUNOCORE HOLDINGS PLC-ADR (IMCR) has a profitability rating of 3 / 10.


Can you provide the financial health for IMCR stock?

The financial health rating of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is 3 / 10.